3Zabransky RJ.Linezolid:the first of a new class of antimicrobial agents[J].Clin Microb Newslett,2002,24(4):25-30.
4Gerson SL,Kaplan SL,Bruss JB,et al.Hematologic effects of linezolid:summary of clinical experience[J].Antimicrob Agents Chemother,2002,46(8):2723-2726.
5Nasraway SA,Shorr AF,Kuter D J,et al.Linezolid does not increase the risk of thromboeytopenia in patients with nosocomial pneumonia:comparative analysis of linezolid and vancomycin use[J].Clin Infect Dis,2003,37(12):1609-1616.
6Rao N,Ziran BH,Wagener MM,et al.Similar hematologic effects of long-term linezolid and vancomyein therapy in a prospective observational study of patients with orthopedic infections[J].Clin Infect Dis,2004,38(8):1058-1004.
7Grau S,Morales-Molina JA,Mateu-de Antonio J,et al.Linezolid:low pre-treatment platelet values could increase the risk of thrombocytopenia[J].J Antimicrob Chemother,2005,56(2):440-441.
8Grim SA,Rene L,Gupta S,et al.Safety of linezolid in patients with baseline thrombocytopenia[J].J Antimicrob Chemother,2008,62(4):850-851.
9Rubinstein E,Isturiz R,Standiford HC,et al.Worldwide assessment of linezolid's clinical safety and tolerability:comparator-controlled phase Ⅲ studies[J].Antimicrob Agents Chemother,2003,47(6):1824-1831.
10Birmingham MC,Rayner CR,Meagher AK,et al.Linezolid for the treatment of muhidrug-resistant,Grampositive infections:experience from a compassionate-use program[J].Clin Infect Dis,2003,36(2):159-168.
